RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Leake, Kathryn ^a   Singhal, Jyotsana ^a   Nagaprashantha, Lokesh Dalasanur ^a   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL MEMBRANE PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLINE; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN RLIP76; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RALBP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER REGRESSION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; COLONY FORMATION; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RADIOSENSITIVITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL TRANSFORMATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROTEIN TRANSPORT; RADIATION DOSE; RADIATION EXPOSURE; TREATMENT FAILURE; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GTPASE-ACTIVATING PROTEINS; HUMANS; MICE; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84859231101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034582     Document Type: Article

References (50)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al.eds. (2011) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. Flaks B, (1984) Histogenesis of pancreatic carcinogenesis in the hamster: ultrastructural evidence. Environ Health Perspect 56: 187-203.
3. Pour PM, (1984) Histogenesis of exocrine pancreatic cancer in the hamster model. Environ. Health Perspect 56: 229-243.
4. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, et al. (2008) Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49: 1408-1413.
5. Freeman JW, Mattingly CA, Strodel WE, (1995) Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 165: 155-163.
6. Korc M, (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7: 25-41.
7. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, et al. (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54: 1556-1560.
8. Agbunag C, Bar-Sagi D, (2004) Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 64: 5659-5663.
9. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, et al. (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67: 2098-2106.
10. Matsumoto J, Kaneda M, Tada M, Hamada J, Okushiba S, et al. (2002) Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells. Jpn J Cancer Res 93: 1317-1326.
11. Perugini RA, McDade TP, Vittimberga FJ, Callery MP, (2000) Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 90: 39-44.
12. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, et al. (2009) Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69: 3689-3694.
13. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE, (2011) Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials. Anticancer Agents Med Chem 11: 455-463.
14. West KA, Castillo SS, Dennis PA, (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248.
15. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R, (2010) Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 10: 1647-1661.
16. Yadav S, Zajac E, Singhal SS, Awasthi S, (2007) Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters. Cancer Metastasis Rev 26: 59-69.
17. Awasthi YC, Yang Y, Tiwari NK, Patrick B, Sharma A, et al. (2004) Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. Free Radic Biol Med 37: 607-619.
18. Marchand DH, Abdel-Monem MM, (1985) Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro. Biochem Biophys Res Commun 128: 360-367.
19. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC, (2003) Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine-kinase signaling and drug-resistance. Int J Cancer 106: 635-646.
20. Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi YC, (2002) RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab Dispos 30: 1300-1310.
21. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, et al. (2010) RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer 126: 1327-1338.
22. Singhal SS, Awasthi YC, Awasthi S, (2006) Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 66: 2354-2360.
23. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor P, et al. (2007) Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (RALBP1). Cancer Res 67: 4382-4389.
24. Singhal SS, Roth C, Leake K, Singhal J, Yadav S, et al. (2009) Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol 77: 1074-1083.
25. Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, et al. (2011) Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Ther 10: 16-28.
26. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, et al. (2000) Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 39: 9327-9334.
27. Awasthi S, Cheng JZ, Singhal SS, Sharma R, Pandya U, et al. (2001) Functional reassembly of ATP-dependent xenobiotic transport by the N- and C-terminal domains of RLIP76: identification of ATP binding sequences. Biochemistry 40: 4159-4168.
28. Awasthi YC, Garg HS, Dao DD, Partridge CA, Srivastava SK, (1981) Enzymatic conjugation of erythrocyte glutathione with 1-chloro-2,4-dinitrobenzene: the fate of glutathione conjugate in erythrocytes and the effect of glutathione depletion on hemoglobin. Blood 58: 733-738.
29. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC, et al. (2005) Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 70: 481-488.
30. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, et al. (2005) RLIP76 transports vinorelbine and mediates drug-resistance in non-small cell lung cancer. Cancer Res 65: 991-998.
31. Singhal SS, Singhal J, Sharma R, Singh SV, Zimniak P, et al. (2003) Role of RLIP76 in lung cancer doxorubicin resistance: The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. Int J Oncol 22: 365-375.
32. Nagaprashantha LD, Vatsyayan R, Singhal J, Lelsani P, Prokai L, et al. (2011) 2′-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma. Carcinogenesis 32: 568-575.
33. Nagaprashantha LD, Vatsyayan R, Singhal J, Fast S, Roby R, et al. (2011) Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol 82: 1100-1109.
34. Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, et al. (2009) RLIP76: a target for kidney cancer therapy. Cancer Res 69: 4244-4251.
35. Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo J-H, et al. (2008) RLIP76 and Cancer. Clin Cancer Res 14: 4372-4377.
36. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083.
37. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, et al. (2007) Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26: 7445-7456.
38. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Alexiou D, et al. (1998) Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res 18: 4177-4180.
39. Sugatani T, Hruska KA, (2005) Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280: 3583-3589.
40. Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, et al. (2004) Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9: 797-805.
41. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. (1992) Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654.
42. Lautier D, Canitrot Y, Deeley RG, Cole SP, (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977.
43. Gottesman MM, Pastan I, (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
44. Ueda K, Cardarelli C, Gottesman MM, Pastan I, (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci 84: 3004-3008.
45. Hipfner DR, Mao Q, Qiu W, Leslie EM, Gao M, et al. (1999) Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein. J Biol Chem 274: 15420-15426.
46. Kokubu N, Cohen D, Watanabe T, (1997) Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Biochem Biophys Res Commun 230: 398-401.
47. Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, et al. (2005) RLIP76 is a major determinant of radiation-sensitivity. Cancer Res 65: 6022-6028.
48. Singhal J, Yadav S, Nagaprashantha LD, Vatsyayan R, Singhal SS, et al. (2011) Targeting p53-null neuroblastomas through RLIP76. Cancer Prev Res 4: 879-889.
49. Takeichi M, (1991) Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455.
50. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, et al. (2008) Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 14: 412-418.